Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$35.31 USD

35.31
115,830

+0.28 (0.80%)

Updated Aug 7, 2025 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.

Zacks Equity Research

Hill-Rom Grows on Acquisitions, Asia Pacific Sales Drop

by Zacks Equity Research

Hill-Rom (HRC) is actively pursuing buyouts to accelerate growth across five key clinical areas.

Zacks Equity Research

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.

Zacks Equity Research

Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.

Zacks Equity Research

Walgreens-Alphabet Join Forces to Control Healthcare Costs

by Zacks Equity Research

Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.

Zacks Equity Research

Here's Why You Should Invest in STERIS (STE) Stock Right Now

by Zacks Equity Research

With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.

Zacks Equity Research

Here's Why You Should Hold HealthEquity (HQY) Stock for Now

by Zacks Equity Research

HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.

Zacks Equity Research

Medtronic's Mazor Buyout Creates a New Spine Surgery Major

by Zacks Equity Research

With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.

Zacks Equity Research

Baxter Stock up on Launch of Disposable Curved Applicator

by Zacks Equity Research

Baxter's (BAX) wide array of surgical products see lucrative market prospects.

Zacks Equity Research

Surmodics Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

GNC Holdings Global Business Strong, Same Store Sales Weak

by Zacks Equity Research

GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.

Zacks Equity Research

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.

Zacks Equity Research

Here's Why You Should Buy Haemonetics (HAE) Stock Right Now

by Zacks Equity Research

Haemonetics (HAE) continues to witness strong growth in Plasma franchise.

Zacks Equity Research

Cerner's (CERN) Millennium Picked by Mid-Valley Hospital

by Zacks Equity Research

Cerner's (CERN) EHR platforms have seen a series of developments in recent times.

Zacks Equity Research

Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look

by Zacks Equity Research

DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.

Zacks Equity Research

Hologic's (HOLX) New Offering to Revitalize Cynosure Division

by Zacks Equity Research

The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.

Zacks Equity Research

Bruker Profits from NANO & CALID, New Buyout Holds Promise

by Zacks Equity Research

Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.

Zacks Equity Research

Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength

by Zacks Equity Research

We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.

Zacks Equity Research

Varian Medical's Eclipse Picked by Paul Scherrer Institute

by Zacks Equity Research

Varian Medical's (VAR) latest developments fortify its foothold in the global cancer therapeutics market.

Zacks Equity Research

Here's Why You Should Hold Baxter International (BAX) Now

by Zacks Equity Research

Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.

Zacks Equity Research

Edwards Lifesciences Advances in AI With Bay Labs Tie-Up

by Zacks Equity Research

Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.

Zacks Equity Research

CVS Health Aetna Synergy Impressive, PBM Selling Season Solid

by Zacks Equity Research

CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.

Zacks Equity Research

STERIS Rides on Favorable Industry Trends, Rivalry a Concern

by Zacks Equity Research

STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.

Zacks Equity Research

NuVasive's Monolith Corpectomy System Ok'd for Expanded Use

by Zacks Equity Research

NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.

Zacks Equity Research

Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm

by Zacks Equity Research

Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.